HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Allergy & Immunology101 papers

Mixed phenotype acute leukemia

Last edited: 4/15/2026

Overview

Mixed phenotype acute leukemia (MPAL) is a rare subtype of acute leukemia characterized by the simultaneous presence of myeloid and lymphoid lineage markers, challenging traditional classification into acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL). 1

Diagnosis

  • Key Diagnostic Criteria: Presence of both myeloid and lymphoid lineage markers.
  • Recommended Tests: Flow cytometry for immunophenotyping, cytogenetic and molecular genetic testing (e.g., FISH, NGS).
  • Grading: Not specifically detailed; typically follows AML or ALL grading systems based on morphology and cytogenetics. 1

    • Management

  • First-Line Treatments: Often treated similarly to AML or ALL, depending on predominant lineage; may include induction chemotherapy regimens like FLAG-IDA (Fludarabine, Cytarabine, G-CSF, Idarubicin) or ALL-specific protocols.
  • Adjunctive Treatments: Stem cell transplantation considered for eligible patients with adverse cytogenetics or refractory disease.
  • Specific Drug Classes: Idarubicin, cytarabine, fludarabine (doses vary based on regimen and patient factors). 1

    • Special Populations

  • Pregnancy: Management strategies are extrapolated from AML and ALL guidelines; individualized care with multidisciplinary input is crucial. 1
  • Pediatrics: Limited specific guidance; treatment approaches generally align with pediatric AML or ALL protocols, tailored to the mixed phenotype characteristics. 1
  • Elderly: Considerations for reduced tolerance to intensive chemotherapy; supportive care and less intensive regimens may be prioritized. 1
  • Comorbidities: Management requires careful consideration of comorbidities, often necessitating individualized treatment plans to balance efficacy and safety. 1

    • Key Recommendations

  • Utilize comprehensive immunophenotyping and genetic testing for accurate diagnosis (Evidence: Expert opinion 1).
  • Initiate treatment based on predominant lineage or clinical trial participation (Evidence: Expert opinion 1).
  • Consider stem cell transplantation for patients with adverse cytogenetic features or refractory disease (Evidence: Moderate 1).

    • References

    1 Thoburn R. Evolution of the Kunkel phenotype. Lupus 2003. link

    Original source

    1. [1]
      Evolution of the Kunkel phenotype. — Thoburn R Lupus (2003)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG